Peptides Similar to Eloralintide
Compare Eloralintide with related peptides and alternatives
📌TL;DR
- •5 similar peptides identified
- •Cagrilintide: High - Both are long-acting amylin receptor agonists for obesity. Both are acylated amylin analogs with once-weekly subcutaneous dosing.
- •Petrelintide: High - Both are next-generation amylin receptor agonists developed for obesity treatment with once-weekly subcutaneous dosing.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Eloralintide (current) | - | - |
| Cagrilintide | High - Both are long-acting amylin receptor agonists for obesity. Both are acylated amylin analogs with once-weekly subcutaneous dosing. | Eloralintide is AMY1R-selective (12-fold over CTR) while cagrilintide is non-selective across amylin and calcitonin receptors. Preclinical data suggest eloralintide has better GI tolerability and quality of weight loss. |
| Petrelintide | High - Both are next-generation amylin receptor agonists developed for obesity treatment with once-weekly subcutaneous dosing. | Petrelintide (Novo Nordisk) showed 8.6% weight loss at 16 weeks in early data. Eloralintide demonstrated 20.1% at 48 weeks. Different selectivity profiles and pharmacokinetic properties. |
| Tirzepatide | Moderate - Both target obesity through peptide-based mechanisms with once-weekly SC dosing. Eli Lilly develops both. | Tirzepatide is a dual GLP-1/GIP agonist; eloralintide is an amylin agonist. Completely distinct receptor targets and mechanisms of action. Tirzepatide is FDA-approved; eloralintide is in Phase 3. |
| Semaglutide | Moderate - Both are injectable peptides for obesity with once-weekly dosing and significant weight loss efficacy. | Semaglutide is a GLP-1 receptor agonist; eloralintide acts on amylin receptors. Different mechanism of action, adverse effect profiles, and regulatory status. Semaglutide is approved; eloralintide is Phase 3. |
| Retatrutide | Low-Moderate - Both are Eli Lilly injectable peptides for obesity, but they target completely different receptor systems. | Retatrutide is a triple agonist (GLP-1/GIP/glucagon); eloralintide is an amylin agonist. Retatrutide achieved up to 24% weight loss at 48 weeks in Phase 2. Different mechanisms and adverse effect profiles. |
CagrilintideHigh - Both are long-acting amylin receptor agonists for obesity. Both are acylated amylin analogs with once-weekly subcutaneous dosing.
Differences
Eloralintide is AMY1R-selective (12-fold over CTR) while cagrilintide is non-selective across amylin and calcitonin receptors. Preclinical data suggest eloralintide has better GI tolerability and quality of weight loss.
Advantages
AMY1R selectivity may reduce nausea; preclinical evidence of preferential fat mass loss; Phase 2 shows up to 20.1% weight loss as monotherapy.
Disadvantages
Less advanced clinically than cagrilintide (which has Phase 3 data as CagriSema combination); no approved combination product pathway yet.
PetrelintideHigh - Both are next-generation amylin receptor agonists developed for obesity treatment with once-weekly subcutaneous dosing.
Differences
Petrelintide (Novo Nordisk) showed 8.6% weight loss at 16 weeks in early data. Eloralintide demonstrated 20.1% at 48 weeks. Different selectivity profiles and pharmacokinetic properties.
Advantages
More extensive published clinical data; higher peak weight loss demonstrated; published receptor selectivity characterization.
Disadvantages
Earlier in clinical development than petrelintide Phase 3 programs; direct comparison not available.
TirzepatideModerate - Both target obesity through peptide-based mechanisms with once-weekly SC dosing. Eli Lilly develops both.
Differences
Tirzepatide is a dual GLP-1/GIP agonist; eloralintide is an amylin agonist. Completely distinct receptor targets and mechanisms of action. Tirzepatide is FDA-approved; eloralintide is in Phase 3.
Advantages
Mechanistically distinct, enabling potential combination therapy. May offer weight loss through amylin pathway for non-responders to incretin therapy.
Disadvantages
Investigational vs approved; less extensive clinical data; lower peak weight loss demonstrated (20.1% vs ~22.5% for tirzepatide 15 mg).
SemaglutideModerate - Both are injectable peptides for obesity with once-weekly dosing and significant weight loss efficacy.
Differences
Semaglutide is a GLP-1 receptor agonist; eloralintide acts on amylin receptors. Different mechanism of action, adverse effect profiles, and regulatory status. Semaglutide is approved; eloralintide is Phase 3.
Advantages
Distinct mechanism offers combination potential. AMY1R selectivity may provide different tolerability profile.
Disadvantages
Investigational status; less extensive safety database; no cardiovascular outcome trial data.
RetatrutideLow-Moderate - Both are Eli Lilly injectable peptides for obesity, but they target completely different receptor systems.
Differences
Retatrutide is a triple agonist (GLP-1/GIP/glucagon); eloralintide is an amylin agonist. Retatrutide achieved up to 24% weight loss at 48 weeks in Phase 2. Different mechanisms and adverse effect profiles.
Advantages
Mechanistically complementary to incretin agonists. May be used in combination with GLP-1/GIP-based therapies.
Disadvantages
Lower peak weight loss than retatrutide in Phase 2; earlier in clinical development.
Peptides Related to Eloralintide#
Eloralintide occupies a distinct position in the anti-obesity landscape as the only AMY1R-selective amylin agonist in late-stage clinical development. Relevant comparisons include other amylin-based therapies targeting the same pathway and incretin-based therapies that represent the current standard of care.
Amylin Receptor Agonists#
Cagrilintide (Novo Nordisk)#
Cagrilintide is the most direct competitor to eloralintide. It is a long-acting amylin analog developed by Novo Nordisk, primarily as the amylin component of CagriSema (cagrilintide + semaglutide combination).
Key differences: Cagrilintide activates amylin and calcitonin receptors non-selectively, whereas eloralintide is 12-fold selective for AMY1R over CTR. In preclinical head-to-head comparisons, eloralintide induced less conditioned taste avoidance (a nausea proxy) and produced preferential fat mass loss with less lean mass depletion.
Clinical context: Cagrilintide monotherapy (2.4 mg weekly) achieved 11.5% weight loss at 68 weeks in Phase 3. Eloralintide 9 mg achieved 20.1% at 48 weeks in Phase 2. Direct comparison is not possible due to different trial designs, populations, and durations.
Petrelintide (Novo Nordisk)#
Petrelintide is another next-generation amylin analog from Novo Nordisk. Early clinical data showed 8.6% weight loss at 16 weeks. It is being developed for both monotherapy and combination use but has less published characterization than eloralintide.
Incretin-Based Therapies#
Tirzepatide (Eli Lilly)#
Tirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). In the SURMOUNT-1 trial, tirzepatide 15 mg achieved approximately 22.5% weight loss at 72 weeks.
Complementary mechanism: Eli Lilly is developing eloralintide as a potential combination partner for tirzepatide. Because amylin and GLP-1/GIP act through distinct receptor pathways, combination therapy could produce additive or synergistic effects. A Phase 2 combination study is ongoing.
Semaglutide (Novo Nordisk)#
Semaglutide 2.4 mg (Wegovy) is the first GLP-1 agonist approved specifically for weight management, achieving approximately 15% weight loss at 68 weeks. Novo Nordisk's combination approach pairs semaglutide with cagrilintide (CagriSema).
Comparison Table#
| Feature | Eloralintide | Cagrilintide | Tirzepatide | Semaglutide |
|---|---|---|---|---|
| Class | Selective amylin agonist | Non-selective amylin agonist | GLP-1/GIP agonist | GLP-1 agonist |
| Target | AMY1R (selective) | AMY1-3R + CTR | GLP-1R + GIPR | GLP-1R |
| Route | SC weekly | SC weekly | SC weekly | SC weekly |
| Peak weight loss | ~20% (48 wk, Ph2) | ~11.5% (68 wk, Ph3 mono) | ~22.5% (72 wk, Ph3) | ~15% (68 wk, Ph3) |
| GI tolerability | Favorable (selective) | Moderate (non-selective) | Moderate | Moderate |
| Body composition | Preferential fat loss (preclinical) | Not characterized | Under investigation | Under investigation |
| Developer | Eli Lilly | Novo Nordisk | Eli Lilly | Novo Nordisk |
| Status | Phase 3 | Phase 3 (CagriSema) | Approved | Approved |
Competitive Landscape#
The anti-obesity drug landscape is evolving rapidly. Eloralintide's competitive positioning rests on:
- Mechanistic differentiation: The only AMY1R-selective agonist, potentially offering a better tolerability-to-efficacy ratio than non-selective amylin analogs
- Combination potential: Designed to complement Lilly's existing tirzepatide franchise through amylin pathway activation
- Monotherapy efficacy: 20.1% weight loss approaches that of leading incretin therapies, offering an alternative for patients who do not tolerate or respond to GLP-1 agonists
- Body composition: Preclinical evidence of preferential fat loss could differentiate eloralintide if confirmed in human trials
Related Reading#
Frequently Asked Questions About Eloralintide
What are the main alternatives to eloralintide?
The primary alternatives include other amylin agonists (cagrilintide, petrelintide) and GLP-1-based therapies (semaglutide, tirzepatide, retatrutide). Each has a different mechanism and clinical development stage. Eloralintide is unique in its AMY1R selectivity.
How does eloralintide compare to cagrilintide?
Both are long-acting amylin analogs for obesity, but eloralintide is AMY1R-selective while cagrilintide is non-selective. Preclinical data suggest eloralintide has less nausea and better quality of weight loss (preferential fat loss). Cagrilintide is more advanced clinically as part of CagriSema (combination with semaglutide).
Can eloralintide be combined with GLP-1 agonists?
Eli Lilly is evaluating eloralintide in combination with tirzepatide in an ongoing Phase 2 trial. Because amylin and GLP-1 act through distinct receptor pathways, combination therapy may produce additive weight loss. Results from this study are pending.
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer